Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Chlamydia Infection Diagnostics and Therapeutics Market: By Diagnostics, By Therapeutics Others), By End-user Region Forecast 2019-2030
Chlamydia Infection Diagnostics And Therapeutics Market size was valued at US$ 2.6 billion in 2023 and is poised to grow at a CAGR of 6.1% from 2024-2030. Chlamydia is a sexually transmitted disease (STD) caused by the bacteria Chlamydia trachomatis, and it can be transmitted to a baby at birth. chlamydia infection diagnostics and therapeutics market usually does not have any symptoms but often infected may have symptoms such as genital pain and genital discharge both in men and women. Furthermore, chlamydia infection can cause health complications such as preventing women from getting pregnant or even endangering their pregnancies. Some people may experience pain in the lower abdomen, pelvis, testicle, or vagina and may also have eye discharge or spotting. Treatment may include antibiotics and anti-inflammatory agents, and a hospital stay may be required.
The global chlamydia infection diagnostics and therapeutics market is growing at significant rates owing to the prevalence rate of sexually transmitted diseases. According to the World Health Organization (WHO), worldwide, more than one million sexually transmitted infections are acquired every day. Each year, an estimated of 131 million new cases of chlamydia infection are reported. Companies are focusing on the development of new ways to detect chlamydia infection in the initial stages. For instance, in December 2016, F. Hoffmann-La Roche AG launched Cobas 6800/8800 systems for the detection of Chlamydia trachomatis and Neisseria Gonorrhoea (NG) DNA.
Study Period
2025-2031Base Year
2024CAGR
6.1%Largest Market
North-AmericaFastest Growing Market
North-America
Global chlamydia infection diagnostics and therapeutics market is mainly driven by an increase in prevalence of sexually transmitted diseases worldwide. Furthermore, emergence of rapid test and advances in biotechnology are expected to boost the chlamydia infection diagnostics and therapeutics market. In addition, increase in R&D activities towards development of therapeutics for antibiotic-resistant bacteria and initiatives by government and non-government agencies (such as World Health Organization (WHO) to increase awareness about STD and their symptoms are expected to bolster the chlamydia diagnostics and therapeutics market during the forecast period. However, high cost of development, stringent regulatory procedures for the approval and bacterial drug resistance is expected to hamper the chlamydia infection diagnostics and therapeutics market.
Report Benchmarks |
Details |
Report Study Period |
2025-2031 |
Market Size in 2023 |
US$ 2.6 billion |
Market CAGR |
6.1% |
By Diagnostics |
|
By Therapeutics |
|
By End-user |
|
By Region |
|
Download Free Sample Report
The global chlamydia infection diagnostics and therapeutics market size was valued at US$ 2.6 billion in 2023 and is projected to grow at a CAGR of 6.1% from 2024-2030
Abbott Laboratories, Bio-Rad Laboratories Inc, Becton Dickinson and Company, bioMérieux, DiaSorin SpA
North America is the fastest-growing region for chlamydia infection diagnostics and therapeutics market
1.Executive Summary |
2.Global Chlamydia Infection Diagnostics And Therapeutics Market Introduction |
2.1.Global Chlamydia Infection Diagnostics And Therapeutics Market - Taxonomy |
2.2.Global Chlamydia Infection Diagnostics And Therapeutics Market - Definitions |
2.2.1.Diagnostics |
2.2.2.Therapeutics |
2.2.3.End-user |
2.2.4.Region |
3.Global Chlamydia Infection Diagnostics And Therapeutics Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Chlamydia Infection Diagnostics And Therapeutics Market Analysis, 2020 - 2024 and Forecast 2025 - 2031 |
4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Chlamydia Infection Diagnostics And Therapeutics Market By Diagnostics, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
5.1. Direct Fluorescent Tests |
5.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Nucleic Acid Amplification Tests |
5.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Others |
5.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
6.Global Chlamydia Infection Diagnostics And Therapeutics Market By Therapeutics, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
6.1. Antibiotics |
6.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Others |
6.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
7.Global Chlamydia Infection Diagnostics And Therapeutics Market By End-user, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
7.1. Hospitals and Hospital Pharmacies |
7.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Retail Pharmacies |
7.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Others |
7.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8.Global Chlamydia Infection Diagnostics And Therapeutics Market By Region, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific (APAC) |
8.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Middle East and Africa (MEA) |
8.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Latin America |
8.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9.North America Chlamydia Infection Diagnostics And Therapeutics Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
9.1. Diagnostics Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Direct Fluorescent Tests |
9.1.2.Nucleic Acid Amplification Tests |
9.1.3.Others |
9.2. Therapeutics Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Antibiotics |
9.2.2.Others |
9.3. End-user Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Hospitals and Hospital Pharmacies |
9.3.2.Retail Pharmacies |
9.3.3.Others |
9.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1.United States of America (USA) |
9.4.2.Canada |
10.Europe Chlamydia Infection Diagnostics And Therapeutics Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
10.1. Diagnostics Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Direct Fluorescent Tests |
10.1.2.Nucleic Acid Amplification Tests |
10.1.3.Others |
10.2. Therapeutics Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Antibiotics |
10.2.2.Others |
10.3. End-user Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Hospitals and Hospital Pharmacies |
10.3.2.Retail Pharmacies |
10.3.3.Others |
10.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Germany |
10.4.2.France |
10.4.3.Italy |
10.4.4.United Kingdom (UK) |
10.4.5.Spain |
11.Asia Pacific (APAC) Chlamydia Infection Diagnostics And Therapeutics Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
11.1. Diagnostics Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Direct Fluorescent Tests |
11.1.2.Nucleic Acid Amplification Tests |
11.1.3.Others |
11.2. Therapeutics Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Antibiotics |
11.2.2.Others |
11.3. End-user Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Hospitals and Hospital Pharmacies |
11.3.2.Retail Pharmacies |
11.3.3.Others |
11.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.China |
11.4.2.India |
11.4.3.Australia and New Zealand (ANZ) |
11.4.4.Japan |
11.4.5.Rest of APAC |
12.Middle East and Africa (MEA) Chlamydia Infection Diagnostics And Therapeutics Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
12.1. Diagnostics Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Direct Fluorescent Tests |
12.1.2.Nucleic Acid Amplification Tests |
12.1.3.Others |
12.2. Therapeutics Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Antibiotics |
12.2.2.Others |
12.3. End-user Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Hospitals and Hospital Pharmacies |
12.3.2.Retail Pharmacies |
12.3.3.Others |
12.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.GCC Countries |
12.4.2.South Africa |
12.4.3.Rest of MEA |
13.Latin America Chlamydia Infection Diagnostics And Therapeutics Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
13.1. Diagnostics Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Direct Fluorescent Tests |
13.1.2.Nucleic Acid Amplification Tests |
13.1.3.Others |
13.2. Therapeutics Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Antibiotics |
13.2.2.Others |
13.3. End-user Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Hospitals and Hospital Pharmacies |
13.3.2.Retail Pharmacies |
13.3.3.Others |
13.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Brazil |
13.4.2.Mexico |
13.4.3.Rest of LA |
14. Competition Landscape |
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
14.2.1.Novartis AG (Switzerland) |
14.2.2.Bio-Rad Laboratories Inc. (U.S.) |
14.2.3.F. Hoffmann-La Roche AG (Switzerland) |
14.2.4.The Danaher Corporation (U.S.) |
14.2.5.Abbott Laboratories (U.S.) |
14.2.6.Siemens AG (Germany) |
14.2.7.DiaSorin SpA (Italy) |
14.2.8.Becton Dickinson and Company (U.S.) |
14.2.9.Thermo Fisher Scientific (U.S.) |
15. Research Methodology |
16. Appendix and Abbreviations |
Key Market Players